Tolvaptan CAS 150683-30-0 API Purity >99.0% (HPLC)
Manufacturer Supply Tolvaptan and Related Intermediates:
Tolvaptan CAS 150683-30-0
7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one CAS 160129-45-3
o-Toluoyl Chloride CAS 933-88-0
4-Amino-2-Methylbenzoic Acid CAS 2486-75-1
2-Methyl-4-Nitrobenzoic Acid CAS 1975-51-5
Name | Tolvaptan |
Chemical Name | N-[4-(9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide |
CAS Number | 150683-30-0 |
CAT Number | RF-API101 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C26H25ClN2O3 |
Molecular Weight | 448.94 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Off-White Crystalline Powder |
Identification Methods | IR, HPLC |
Solubility | Soluble in Benzyl Alcohol and Methanol but Practically Insoluble in Water and Hexane |
Purity / Analysis Method | >99.0% (HPLC) |
Melting Point | 219.0~222.0℃ |
Loss on Drying | <0.50% |
Residue on Ignition | <0.10% |
Single Impurity | <0.50% |
Total Impurities | <1.00% |
Heavy Metals | ≤20ppm |
Residual Solvents | Meet the Specification |
Test Standard | Enterprise Standard |
Usage | API; Pharmaceutical Intermediates |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Tolvaptan (CAS: 150683-30-0), also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Otsuka Pharmaceutical licensed tolvaptan under the trade name Samsca after the FDA approved the drug in May 2009. Tolvaptan has also shown efficacy against polycystic kidney disease. In a 2004 trial, tolvaptan administered with traditional diuretics was noted to increase excretion of excess fluids and improve blood sodium levels in patients with heart failure without producing side effects such as hypotension (low blood pressure) or hypokalemia (decreased blood levels of potassium). The drug also exhibited no adverse effect on kidney function.